VogelsteinPetrocheilos 1

Catalio Capital Management, an investment firm with offices in Baltimore and New York City, this week announced the close of a new fund that already counts a Johns Hopkins University-borne cancer detection company and patient-monitoring software system in its portfolio.

According to Catalio executives, the $85 million Catalio Credit Opportunities Fund I partners with what a statement called “39 world-renowned serial scientist-entrepreneurs at top-tier academic institutions in the US and Europe in order to vet opportunities to fund founders.” The fund, also described as a “special situations fund,” targets small and mid-sized private companies.

Image: (L to R) Catalio Capital Management cofounders R. Jacob Vogelstein and George Petrocheilos. (Courtesy photo)

Linshom medical logo

BALTIMORE, MARYLAND, UNITED STATES, November 8, 2022 /EINPresswire.com/ -- Linshom Medical was awarded a $2.4 Million Fasttrack SBIR grant from the National Institutes of Health (NIH), National Heart Lung and Blood Institute (NHLBI).

“This award further validates our technology for critical bedside respiratory monitoring and adds to the list of Linshom Medical’s achievements,” said Richard Hughen, CEO. “This award funds a clinical study to prove Linshom’s early detection capability of patient respiratory decline. It also funds the further miniaturization of our technology to reach more patients in more settings such as a nasal cannula and a wearable sensor for home monitoring.”

NCATS Director Joni L. Rutter, Ph.D.

Lawrence A. Tabak, D.D.S., Ph.D., who is performing the duties of the National Institutes of Health director, has selected Joni L. Rutter, Ph.D., as director of NIH’s National Center for Advancing Translational Sciences (NCATS). Dr. Rutter has served as NCATS acting director since April 2021. She officially began her role as NCATS director on Nov. 6, 2022.

Image: NCATS Director Joni L. Rutter, Ph.D.

Us capitol building 2021 08 26 18 19 19 utc

Under the SBIR and STTR Extension Act of 2022 (the Act), signed into law last month, the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs were extended through fiscal year 2025. These programs provide grants or contracts to small businesses to fund early-stage research and development. Over a dozen agencies participate in the SBIR or STTR programs, including the U.S. Department of Defense, the U.S. Department of Energy, and NASA. According to the Small Business Administration, more than 5,000 new awards, amounting to over $3 billion, are made each year under these programs. The complete list and link to each agency's website (including current opportunities) can be found here.

 

Screen Shot 2022 11 01 at 2 51 27 PM

An Orange County-based startup, Innovation Lab, announced that it was awarded $30,000 in grant funding to help bring its “Move-D” mechanical elbow brace to market to help improve Activities of Daily Living (ADL) for pediatric ataxic cerebral palsy patients. The grant was awarded during the “Make Your Medical Device Pitch for Kids!” competition held during the 10th Annual Pediatric Device Innovation Symposium hosted by Children’s National Hospital on October 23, 2022.

 

914af581 565f 4304 9500 30abc9ed456e

Join this collaborative webinar between MedTech Color and the National Institutes of Health on November 8th 2022 at 2:30 PM ET. Attendees will learn about the NIH programs and initiatives relevant to diverse founders and entrepreneurs in the Medtech space including SBIR/STTR funding and related NIH programs for entrepreneurs. Hear from specific institutes and departments, such as the NIH Small business Education and Entrepreneurial Development (SEED), National Heart, Lung, and Blood Institute (NHLBI), and more, further describe their specific programs, have an open dialogue, and ask questions regarding best fit programs, resources and more!

MedTech Color aims to advance diversity, equity, inclusion, and belonging (DEIB) measures in the medical device industry for underrepresented ethnic minority groups. Their core objectives are: to increase the number of leaders of color who enter and stay in Medtech, add tangible value to the industry's ecosystem via thought-leadership and actionable initiatives, and build a strong, diverse network of mentors and sponsors who champion thought leadership and innovative clinical advancement.

To register for the event, visit https://bit.ly/3Fgrvk0.

GCEC LasVegas 2022

HOUSTON – (Nov. 2, 2022) – The largest crowd in the history of the Global Consortium of Entrepreneurship Centers (GCEC) Conference gathered last week in Las Vegas to celebrate creativity and innovation in university-based entrepreneurship education.

The GCEC is made up of more than 250 leading university entrepreneurship programs working together not only to share best practices and develop programs and initiatives, but also to collaborate and help each other advance, strengthen and celebrate the role universities fulfill in educating the entrepreneurs of tomorrow. The Rice Alliance for Technology and Entrepreneurship at Rice University’s Jones Graduate School of Business in Houston is the global headquarters for the GCEC.

 

mimetas logo

LEIDEN, The Netherlands, November 02, 2022 / B3C newswire / -- MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position.

Henk Volberda, chairman of the jury and professor of Strategy & Innovation at the University of Amsterdam: “MIMETAS is world-leading. Since its foundation in 2013, the company has grown considerably, with branches in Europe, the USA, and Asia. It can now count the largest pharmaceutical companies worldwide among its partners. With its miniaturized organs-on-a-chip, MIMETAS has found a promising approach to enable major advancements in the pharmaceutical industry.”

J P Morgan Logos HD

Stephen Squinto, Ph.D., Gaurav Gupta, M.D. and Anya Schiess join J.P. Morgan as Managing Partners

Industry luminaries to act as Strategic Advisors to support new team

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- J.P. Morgan Asset Management today announced the launch of a new life sciences private equity team, Life Sciences Private Capital. The new team will invest in both early and growth stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity, AI/ML platforms, Metabolic Diseases and Neuropsychology.

Emergent Logo

GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s adjuvanted single dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in prior recipients of other investigational alphavirus vaccines. The study demonstrated that the CHIKV VLP vaccine candidate was well-tolerated and immunogenic in both alphavirus vaccine-naïve participants and participants previously vaccinated against the Venezuelan equine encephalitis virus. The findings were presented at the American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting.

“We are pleased with these positive Phase 2 study results that support the potential utility and continued development of a chikungunya vaccine candidate to help prevent chikungunya disease, including in those who have previously received another alphavirus vaccine,” said Chris Cabell, M.D., chief medical officer and SVP clinical development at Emergent BioSolutions. “There are currently no approved vaccines or treatments for chikungunya disease, and we are committed to advancing our program to help address this unmet medical need.”

United Therapeutics Logo

United Therapeutics Corp. (NASDAQ: UTHR) continues to snap up properties near its Silver Spring headquarters — but has largely remained quiet about its long-term plans for the additional space.

The local drugmaker most recently bought a building at 8905 Fairview Road for $11.85 million, according to Montgomery County property records. The transaction, which closed Oct. 5, also includes a parking lot across the street.

Galen Robotics Logo

Ambix Healthcare Partners Leads Funding Round Bringing New Surgical Robot To Market

BALTIMORE, Nov. 1, 2022 /PRNewswire/ -- Galen Robotics, the Digital-Surgery-as-a-Service ™ pioneer, today announced it has completed the 1st close for an oversubscribed Series A round with $15 million in funding, including investment from Ambix Healthcare Partners, from Menlo Park, CA.

Galen Robotics has submitted a new collaborative soft tissue surgical robot, intended to address unmet needs in the market, to FDA for consideration.  Galen plans to level the surgical playing field by erasing large capital expenditures associated with today's surgical robots. Galen Robotics will be the first surgical robotics company to launch as  "as-a-service" using the per-usage disposable model. Termed Digital-Surgery-as-a-Service, is a new approach to surgical robotics, clearing the way to capture surgical data and promote continuous improvements of surgical techniques, outcomes, and the training of residents. The Series A helped complete the final robot prototype, and submission to FDA. Funds will also be used to develop a clinical sales team, expand engineering, grow product development, and develop surgeon training programs.

Bruce Lichorowic

Galen Robotics, which is commercializing a surgical robot developed at a Johns Hopkins research lab, has announced the first close of a Series A round, after raising $15 million from investors led by California’s Ambix Healthcare Partners. It simultaneously announced a second close for its Series A worth an additional $5 million.

“We will be the first robotic company to launch using an on-demand business model,” said Galen Robotics CEO Bruce Lichorowic, after the Baltimore startup swiftly pivoted from trying to sell its robots to a so-called “digital-surgery-as-a-service” model. The switch makes Galen’s robotic services more affordable for hospitals that have financially struggled since the coronavirus pandemic amid a sharp drop in elective surgeries.

 

United Therapeutics 05

United Therapeutics is continuing to buy properties near its downtown Silver Spring corporate headquarters at 1040 Spring St.

Dewey Steadman, director of investor relations for the drug manufacturer, confirmed a report in the Washington Business Journal of the purchase of 8905 Fairview Rd. for $11.85 million, including a parking lot across the street.

Image: https://www.sourceofthespring.com